ARTICLE | Company News
Merck, Taiho deal
April 25, 2016 7:00 AM UTC
Merck granted Taiho Japanese co-promotion rights to pembrolizumab. The humanized IgG4 mAb against PD-1 is under review in Japan to treat unresectable metastatic melanoma and unresectable advanced or ...